Scientists hunt for clues to make skin cancer treatment more personal
NCT ID NCT07064330
Summary
This study aims to find biological markers in the blood and tumor that can predict how patients with advanced skin cancer (cutaneous squamous cell carcinoma) will respond to the immunotherapy drug cemiplimab. Researchers will enroll about 30 patients starting this treatment and use advanced lab tests to analyze their immune system. The goal is to better understand why some patients benefit while others do not, and to identify who might be at risk for side effects, moving toward more personalized care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complejo Asistencial Universitario de Salamanca
RECRUITINGSalamanca, Salamanca, 37007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.